Jones Day advised Bryan, Garnier & Co Limited and Chardan Capital Markets, LLC on the deal. GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the “Company“),…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
